Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Founded in July 2001 by John Dyson and Michael Panaccio, Starfish Ventures is based in Melbourne, Australia. The firm has raised over AU$400 million across three funds, including the PreSeed Fund and Technology Funds I and II. With a portfolio of over 60 companies, Starfish has achieved 14 trade sales and IPOs, including listings on NASDAQ, AIM, and ASX.
Starfish Ventures invests in high growth sectors, particularly in biotech and healthcare. They target pre-seed, seed, Series A, and growth equity stages, providing investments that help entrepreneurs expand teams, build products, and scale globally. Their approach emphasizes partnerships with founders to achieve successful exits.
Notable companies in Starfish Ventures' portfolio include SIRTeX Medical Ltd (ASX listed), ImpediMed Ltd (ASX listed), Protagonist Therapeutics Inc (NASDAQ listed), Engana Pty Ltd (now part of Finisar Corporation), and Energy Response Pty Ltd (sold to EnerNoc Inc).
Submit your pitch through their form at starfishvc.com.
Yes, Starfish Ventures often leads investment rounds, particularly in the pre-seed and seed stages.
The firm actively participates in follow-on investments to support portfolio companies as they grow and scale.
Starfish Ventures has raised over AU$400 million across three funds, focusing on high growth sectors.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.